tiprankstipranks
Trending News
More News >
Nihon Kohden Corporation (JP:6849)
:6849
Japanese Market
Advertisement

Nihon Kohden Corporation (6849) AI Stock Analysis

Compare
0 Followers

Top Page

JP:6849

Nihon Kohden Corporation

(6849)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
¥1,931.00
▲(9.97% Upside)
Nihon Kohden Corporation's stock score is driven by its strong financial performance and fair valuation. The technical analysis suggests a neutral market sentiment, with no significant momentum. The absence of earnings call data and corporate events means these factors do not influence the score.

Nihon Kohden Corporation (6849) vs. iShares MSCI Japan ETF (EWJ)

Nihon Kohden Corporation Business Overview & Revenue Model

Company DescriptionNihon Kohden Corporation (6849) is a leading Japanese manufacturer of medical electronic equipment, specializing in the development, production, and sales of a wide range of healthcare devices. The company operates primarily in the medical sector, providing advanced monitoring, diagnostic, and therapeutic equipment. Its core products include patient monitors, electrocardiographs, electroencephalographs, and a variety of laboratory systems, which are essential in hospitals and healthcare facilities worldwide.
How the Company Makes MoneyNihon Kohden generates revenue primarily through the sale of its medical equipment and related services. The company’s key revenue streams include product sales, which encompass patient monitoring systems, diagnostic devices, and laboratory instruments. Additionally, Nihon Kohden earns income from maintenance services and support for its equipment, ensuring ongoing revenue from existing installations. The company benefits from strategic partnerships with healthcare institutions and distributors, which help expand its market reach and enhance product visibility. Furthermore, continuous investment in research and development allows Nihon Kohden to innovate and introduce new technologies, enabling it to capture additional market share and maintain competitive advantages in the healthcare industry.

Nihon Kohden Corporation Financial Statement Overview

Summary
Nihon Kohden Corporation shows a solid financial position with strong revenue growth and efficient cost management. The low leverage and high equity ratios underscore financial stability, while operational cash flows remain robust. However, declining net profit margins and free cash flow highlight areas for improvement.
Income Statement
75
Positive
Nihon Kohden Corporation has demonstrated strong revenue growth, with a 7.8% increase from 2023 to 2025. The company maintains a healthy gross profit margin around 50.7% in 2025, indicating efficient cost management. However, the net profit margin has slightly decreased from 7.7% in 2024 to 6.3% in 2025 due to increased expenses. The EBIT and EBITDA margins remain robust, showcasing operational efficiency.
Balance Sheet
80
Positive
The company exhibits a strong balance sheet with a low debt-to-equity ratio of 0.15 in 2025, reflecting prudent financial management and low leverage risk. Stockholders' equity has grown consistently, contributing to high equity ratio stability at 69.8%. Return on equity is healthy at 7.8%, although it has decreased from previous years due to lower net income.
Cash Flow
70
Positive
Nihon Kohden's cash flow management is commendable, with a positive operating cash flow to net income ratio of 1.08 in 2025, indicating strong cash generation from operations. The free cash flow to net income ratio has decreased, reflecting higher capital expenditures. Free cash flow has notably decreased by 24.6% in 2025 compared to 2024, pointing to increased investment activities.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue229.22B225.42B221.99B206.60B205.13B199.73B
Gross Profit121.62B114.30B111.35B105.93B109.09B102.23B
EBITDA26.32B25.91B33.25B28.52B37.76B31.64B
Net Income13.47B14.10B17.03B17.11B23.43B18.24B
Balance Sheet
Total Assets247.07B257.24B233.23B216.73B210.20B193.03B
Cash, Cash Equivalents and Short-Term Investments44.51B43.43B50.43B44.46B60.92B44.61B
Total Debt26.03B26.08B654.00M441.00M359.00M404.00M
Total Liabilities69.54B75.94B52.15B49.13B53.82B54.05B
Stockholders Equity175.82B179.55B181.08B167.60B156.38B138.98B
Cash Flow
Free Cash Flow14.54B8.16B10.82B-10.77B22.77B10.56B
Operating Cash Flow21.74B15.29B15.61B-2.51B25.70B13.95B
Investing Cash Flow-25.18B-25.14B-5.21B-7.65B-4.30B-2.95B
Financing Cash Flow2.55B2.55B-6.97B-7.49B-7.30B-3.01B

Nihon Kohden Corporation Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1756.00
Price Trends
50DMA
1716.34
Positive
100DMA
1691.87
Positive
200DMA
1820.57
Negative
Market Momentum
MACD
17.22
Positive
RSI
49.84
Neutral
STOCH
27.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6849, the sentiment is Negative. The current price of 1756 is below the 20-day moving average (MA) of 1774.10, above the 50-day MA of 1716.34, and below the 200-day MA of 1820.57, indicating a neutral trend. The MACD of 17.22 indicates Positive momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 27.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6849.

Nihon Kohden Corporation Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
¥9.28B12.533.63%3.38%88.65%
¥16.16B15.753.63%-8.07%-38.21%
¥289.73B21.121.82%4.43%-1.39%
¥31.04B10.512.67%7.99%28.81%
¥74.45B34.682.38%3.80%6.68%
€131.79B11.598.31%4.07%0.70%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6849
Nihon Kohden Corporation
1,755.00
-495.31
-22.01%
JP:6523
PHC Holdings Corp.
1,031.00
69.93
7.28%
JP:4549
Eiken Chemical Co., Ltd.
2,350.00
-71.78
-2.96%
JP:5187
Create Medic Co., Ltd.
1,019.00
134.53
15.21%
JP:6678
Techno Medica Co., Ltd.
1,875.00
135.18
7.77%
JP:6823
Rion Co., Ltd.
2,524.00
104.68
4.33%

Nihon Kohden Corporation Corporate Events

Nihon Kohden’s New Study on SpO2 Accuracy in Children: Market Implications
Oct 27, 2025

Nihon Kohden Corporation is spearheading a new clinical study titled ‘Evaluation of SpO2 Accuracy in Children With Various Skin Color’. The study aims to assess the accuracy of blood oxygen level measurements in children with different skin tones, addressing a significant gap in pediatric healthcare and ensuring equitable medical care across diverse populations.

Nihon Kohden’s Innovative Approach to Hemodynamic Measurement: A Game Changer?
Oct 27, 2025

The recent clinical study update from Nihon Kohden Corporation, titled ‘Comparison Study of EzCVP and CVP,’ aims to evaluate the effectiveness of a non-invasive method for measuring central venous pressure (CVP) against the traditional invasive approach. This study is significant as it could revolutionize how heart failure, specifically congestive heart failure, is monitored, potentially improving patient outcomes and reducing procedure-related risks.

Nihon Kohden’s Innovative Heart Failure Study: Market Implications and Progress
Oct 27, 2025

Study Overview: Nihon Kohden Corporation is conducting a pilot study titled Pilot Study for the Evaluation of EzCVP in Heart Failure Patients. The study aims to evaluate changes in non-invasive central venous pressure (CVP) in heart failure patients during their hospital stay and its relationship with readmission rates. This research is significant as it could lead to improved monitoring and management of heart failure, potentially reducing hospital readmissions.

Nihon Kohden Ends Abbott Partnership, Launches Employee Support Programs
Sep 29, 2025

Nihon Kohden Corporation has announced the termination of its distribution partnership with Abbott Medical Japan LLC, effective December 31, 2026, as part of its strategic business portfolio review. In response, the company is implementing two support programs: the Career Change Support Program for employees involved in the Abbott business, and the Next Career Support Program for employees seeking new career opportunities or early retirement. These initiatives are expected to result in extraordinary losses of approximately ¥2.4 billion in FY2025, but a reduction in SG&A expenses by around ¥2.3 billion in FY2026.

The most recent analyst rating on (JP:6849) stock is a Buy with a Yen1898.00 price target. To see the full list of analyst forecasts on Nihon Kohden Corporation stock, see the JP:6849 Stock Forecast page.

Nihon Kohden Ends Abbott Partnership to Focus on In-House Growth
Sep 29, 2025

Nihon Kohden Corporation has announced the termination of its distribution partnership with Abbott Medical Japan LLC, effective December 31, 2026. This decision aligns with Nihon Kohden’s strategy to transform its business portfolio and focus on its own products, aiming for long-term growth in the domestic market. The transition will be phased to ensure minimal disruption to patients and medical institutions, with the impact on financial results expected to be minor.

The most recent analyst rating on (JP:6849) stock is a Buy with a Yen1898.00 price target. To see the full list of analyst forecasts on Nihon Kohden Corporation stock, see the JP:6849 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 30, 2025